Skip to content

Multimodal imaging study using Florzolotau PET and brain MRI for the patients with frontotemporal lobar degeneration and atypical Parkinsonism

Multimodal imaging study using Florzolotau PET and brain MRI for the patients with frontotemporal lobar degeneration and atypical Parkinsonism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008805
Enrollment
120
Registered
2023-09-21
Start date
2024-09-02
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Gachon University Gil Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient Group: Patients who visited the neurology department at GMC (Patients should be adults, aged 20 or older, and meet the following conditions for research enrollment) -Frontotemporal dementia (FTD) Probable FTD patients according to the revised guidelines for the diagnosis of behavioral variant FTD by the international consortium (2011), -Atypical parkinsonism Probable progressive supranuclear palsy (PSP) patients according to the Movement Disorder Society Criteria for the clinical diagnosis of PSP (2017). Probable corticobasal degeneration (CBD) patients according to the criteria for the diagnosis of CBD (2013). Normal Control Group : Normal individuals who do not have neurologic or psychiatric diseases and have normal cognitive function (n=30) -People aged 40-85 years old who have agreed to participate in the study and have no neurological or psychiatric disorders. -Participant without a family history of dementia, Parkinson's disease, or schizophrenia. -Participant with normal cognitive function according to neuropsychological tests. -Participant who does not meet any other exclusion criteria.

Exclusion criteria

Exclusion criteria: 1) The following individuals are excluded from the patient group selection process: -Pregnant women (those who are suspected of being pregnant at all are excluded from the study subjects by identifying pregnancy status and the date of the last menstrual period through a survey). -Women who are currently breastfeeding -Patients whose overall physical condition is so poor that it is difficult to perform the examination. -People with seizure symptoms such as claustrophobia or other epilepsy -Patients who have had a large-sized stroke in the brain, brainstem, or cerebellum -Patients with brain tumors, varicella, encephalitis, metabolic brain diseases -Women who are pregnant or have an intrauterine contraceptive device -Individuals who are deemed inappropriate by clinical trial researchers for reasons other than the above items -Individuals with a cardiac pacemaker or metallic material inserted into the body (except for those who have titanium or titanium alloys implanted/transplanted and those who have been confirmed by a specialist to have no problem with a 3T MRI scan). 2) The following individuals are excluded from the normal control group selection process: -Pregnant women (those who are suspected of being pregnant at all are excluded from the study subjects by identifying pregnancy status and the date of the last menstrual period through a survey). -Women who are currently breastfeeding -Researchers or students within the research institution who are deemed difficult to voluntarily participant -Patients whose overall physical condition is so poor that it is difficult to perform the examination. -Individuals with serious psychiatric problems -People with central nervous system diseases or sequelae of previous neurological disorders affecting cognitive function -People with abnormal findings on past brain MRI or PET scans -People with seizure symptoms such as claustrophobia or other epilepsy -Patients with brain diseases.

Design outcomes

Primary

MeasureTime frame
Validation of Florzolotau and Neuromelanin-sensitive MRI images in frontal dementia and atypical Parkinson's syndrome

Secondary

MeasureTime frame
Correlation Analysis Between Brain Imaging Parameters and Clinical Evaluation

Countries

Korea, Republic of

Contacts

Public ContactYoung Noh

Gachon University Gil Medical Center

dementia9043@gmail.com+82-32-460-9043

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026